Koa Wealth Management LLC cut its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,600 shares of the medical device company’s stock after selling 170 shares during the quarter. Koa Wealth Management LLC’s holdings in DexCom were worth $280,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new stake in DexCom during the fourth quarter valued at about $25,000. Riverview Trust Co boosted its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the 3rd quarter valued at approximately $57,000. Covestor Ltd increased its position in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the period. Institutional investors own 97.75% of the company’s stock.
DexCom Stock Performance
Shares of NASDAQ:DXCM opened at $87.62 on Friday. The stock has a market capitalization of $34.22 billion, a price-to-earnings ratio of 52.47, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The business’s fifty day moving average price is $80.22 and its two-hundred day moving average price is $76.59. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on DexCom
Insider Transactions at DexCom
In other news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by insiders.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
- Five stocks we like better than DexCom
- Airline Stocks – Top Airline Stocks to Buy Now
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How Technical Indicators Can Help You Find Oversold Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Utilities Stocks Explained – How and Why to Invest in Utilities
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.